NCT04112498View on ClinicalTrials.gov

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

February 27, 2023

Study Completion Date

February 27, 2023

Conditions
Cancer
Interventions
DRUG

relatlimab

Specified dose on Specified days

DRUG

nivolumab

Specified dose on Specified days

DRUG

rHuPH20

Specified dose on Specified days

Trial Locations (1)

07601

Local Institution - 0001, Hackensack

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04112498 - A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Biotech Hunter | Biotech Hunter